Telomir Pharmaceuticals, Inc. Common Stock TELO · Stock Open Telomir Pharmaceuticals, Inc. Common Stock in new tab
Telomir Pharmaceuticals, Inc. Common Stock Analysis (TELO)
Is Telomir Pharmaceuticals, Inc. Common Stock a good investment? Telomir Pharmaceuticals, Inc. Common Stock (TELO) is currently trading at 1.13 USD.
Earnings Schedule: Telomir Pharmaceuticals, Inc. Common Stock is expected to release its next earnings report on Sept. 2, 2026. The market consensus estimate for Forward EPS is -0.28.
Investor FAQ
Does Telomir Pharmaceuticals, Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Telomir Pharmaceuticals, Inc. Common Stock?
Telomir Pharmaceuticals, Inc. Common Stock is classified as a Stock.
When is the next earnings date?
The next earnings date is projected to be Sept. 2, 2026. The company currently has a trailing EPS of -1.11.
Company Profile
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Community Discussion